By Mariam Sunny and Michael Erman Feb 26 (Reuters) - Novavax raised its adjusted revenue forecast for 2026 on Thursday, banking on milestone payments from licensing and supply deals for its shots, ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its GAAP profit of $0.11 ...

Novavax reported fourth-quarter earnings of 11 cents, a shift from a loss of 51 cents a year ago. evenue for the fourth quarter was $147 million, a 67% year-over-year increase. Novavax on Thursday ...

Novavax beat analysts’ revenue expectations last quarter, reporting revenues of $70.45 million, down 16.6% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ ...

CSL Seqirus was granted a contract to support flu pandemic preparedness plans for Canada's government. The flu vaccine manufacturer said Friday it would make and deliver millions of doses of ...

Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look ...

GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Thursday reported fourth-quarter earnings of $17.5 million. On a per-share basis, the Gaithersburg, Maryland-based company said ...

Food and Drug Administration (FDA) Commissioner Marty Makary on Friday announced that the agency’s top regulator Vinay Prasad ...

2024-2025 COVID-19 vaccines reduced hospitalization risk by 40% against JN.1 lineage variants. COVID-19 is still a public threat and health concern. Between 2024 and 2025, an estimated 380,000 to ...